(CercleFinance.com) – Nanobiotix announces the signing of a global licensing, co-development and marketing agreement with Janssen, a subsidiary of Johnson & Johnson, for NBTXR3, a product-candidate currently being evaluated for various solid tumor indications.
Under the terms agreed, the company grants Janssen an exclusive license for the development and commercialization of NBTXR3, a worldwide license except for the territories already covered by the license agreement with LianBio.
Nanobiotix will receive short-term support worth up to $60 million. He will additionally be eligible for milestone payments for up to $1.8 billion, and will receive double-digit tiered royalties on net sales.